Publications by authors named "Pierre Kergoat"
Background: Recent studies identified coronavirus disease 2019 (COVID-19) as a risk factor for invasive pulmonary aspergillosis (IPA) but produced conflicting data on IPA incidence and impact on patient outcomes. We aimed to determine the incidence and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA) in mechanically ventilated patients.
Methods: We performed a multicenter retrospective observational cohort study in consecutive adults admitted to 15 French intensive care units (ICUs) in 2020 for COVID-19 requiring mechanical ventilation.
Article Synopsis
- Patients with severe COVID-19 in ICUs have a high risk of blood clots, prompting a study to compare the effects of intermediate-dose versus standard-dose anticoagulation.
- The study included 1,174 patients and found no significant difference in 90-day mortality or ICU stay length between the two dosing groups, but intermediate-dose patients had fewer venous thrombo-embolism (VTE) incidents.
- Both groups experienced similar rates of bleeding complications, indicating that while the doses impacted blood clot rates, they did not affect overall survival or safety.
Background: Among strategies that aimed to prevent acquired infections (AIs), selective decontamination regimens have been poorly studied in the COVID-19 setting. We assessed the impact of a multiple-site decontamination (MSD) regimen on the incidence of bloodstream infections (BSI) and ventilator-associated pneumonia (VAP) in COVID-19 patients receiving mechanical ventilation.
Methods: We performed an ancillary analysis of a multicenter retrospective observational study in 15 ICUs in western France.
Rationale: Early corticosteroid treatment is used to treat COVID-19-related acute respiratory distress syndrome (ARDS). Infection is a well-documented adverse effect of corticosteroid therapy.
Objectives: To determine whether early corticosteroid therapy to treat COVID-19 ARDS was associated with ventilator-associated pneumonia (VAP).